Is it possible that the phase II GBM study results will change significantly, for better or for worse, in
the final analysis of the complete data set?
These results are not final and may therefore change as the study moves towards completion. However, the
fact that the study is at this stage relatively mature, together with the fact that these data have remained extremely stable over time, suggests that the final results will be very similar to the interim analyses that have been presented over the
course of the study.
Why is data from 29 patients reported, when 30 were enrolled to the phase II GBM study?
One patient was removed from the study by the principal investigator due to very poor compliance. That patient is believed to have received less than two weeks
of paxalisib treatment, and all data was deemed unreliable. Consequently, they have been removed from this and all previous analyses. The impact of their removal on the overall data is minimal.
How does the safety profile reported in the phase II GBM study compare to FDA-approved PI3K inhibitors?
While hyperglycemia is a common side effect of all drugs inhibiting PI3Kα, the rates of serious hyperglycemia seen with paxalisib are approximately half
those seen with comparable agents. Rash and mucositis are believed to be primarily mTOR-driven toxicities, and so are not directly comparable with approved PI3K inhibitors, which do not have mTOR activity. Other less common, but serious, toxicities
that have been seen with other agents, including pneumonitis, infection, liver toxicity, hypertension, and GI toxicity, have not been seen with paxalisib. On present evidence, the drug has the potential to achieve a best-in-class safety profile.
Overall Response Rate (ORR) is a common endpoint for phase II oncology trials.
Will that be assessed in the phase II GBM study?
ORR is commonly used as an endpoint in early-phase studies of cancer therapies. In general, it is
considered an inferior endpoint to PFS or OS, and very rarely provides a basis for product approval.
From a technical standpoint, ORR measures the change
in size of an existing tumour. 80% of patients in this study had undergone complete resection prior to joining the study, and so had no measurable tumour at study entry, making ORR impossible to determine. The endpoint will be assessed in the final
analysis in those patients for whom it can be determined but is unlikely to provide significant additional information.
How should the data from the
phase I DIPG study be interpreted?
This is a phase I first-in-paediatric study and the primary objective is to
assess safety and tolerability of paxalisb. The study has successfully met those objectives, achieving a paediatric MTD of 27 mg/m2. This dose will be used in future paediatric studies and has
already been adopted for several children who have received the drug on a compassionate use basis.